Best of ASCO® Toronto Conference 2025: Canadian Achievements in Cancer Research – Dr. Stephen Chia

Best of ASCO® Toronto Conference 2025: Canadian Achievements in Cancer Research – Dr. Stephen Chia

CCTG/BCT MA.40/FINER study (NCT04650581)
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).
Best of ASCO® Toronto Conference 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Co-Chairs

Dr. Aly-Khan Lalani

Dr. Natasha Leighl

Icon Chair Speaker

Speakers

Dr. Stephen Chia

Studies / Trials Discussed

CCTG/BCT MA.40/FINER study (NCT04650581)
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).

Studies/trials discussed:

CCTG/BCT MA.40/FINER study (NCT04650581) A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).
Tagged